Russia's Breakthrough in Affordable SMA Treatments Cuts Costs by 25%

Russia has made progress in treating spinal muscular atrophy (SMA), a rare genetic disorder that weakens muscles over time. The condition occurs when a mutation damages motor neurons in the spinal cord. Recently, the country introduced its first locally produced SMA medication, offering a more affordable option for patients. In April 2024, Russian biotech company Generium launched Lantsens, a domestic version of Spinraza. This drug is priced 25% lower than the original, with a single dose costing 3.8 million rubles instead of Spinraza's 5.1 million rubles. Spinraza, alongside Risdiplam and Zolgensma, remains one of only three globally approved SMA treatments. Zolgensma, in particular, holds the record as the world's most expensive medication, with a single dose exceeding $2 million.

A year later, in April 2025, Biocad registered Nusilara, another SMA drug developed in Russia. Meanwhile, the Federal Medical-Biological Agency (FMBA) continues work on an additional SMA treatment. These efforts align with broader advancements in Russia's pharmaceutical industry, which now produces 345 drugs—including 25 life-saving medications previously unavailable in the country. The nation has also begun manufacturing 992 medical devices that were not produced domestically before. Russia's new SMA drugs provide patients with more accessible treatment options. With Lantsens and Nusilara now available, costs have been reduced compared to imported alternatives. The country's expanding pharmaceutical production also supports broader healthcare improvements.